Table 3.
Demographics data on sarcopenia.
| Ref. | Country of Publication | Study Design | Patients Number | Ethnicity | Sex/Age | Comorbidities | Sarcopenia Diagnostic Measures |
|---|---|---|---|---|---|---|---|
| Chen 2019 b [32] | USA | NR | 75 Osteoporotic/osteopenic (N = 46) Sarcopenic (N = 1) Sarco-osteopenic (N = 15) Non-osteoporotic/non-sarcopenic (N = 13) |
NR | Female 60–85 years |
None | Handgrip dynamometer (grip strength), gait speed, and countermovement jumps |
| He 2020 [80] | China | NR | 186 Sarcopenic (N = 93) Non-sarcopenic (N = 93) |
NR | Sarcopenic 76.15 ± 0.58 years Non-sarcopenic 76.19 ± 0.58 years |
Hypertension, diabetes mellitus | Appendicular skeletal muscle mass (ASM); relative skeletal muscle mass index (ASM/Ht2) |
| He 2021 [81] | China | NR | 186 Sarcopenic (N = 93) Non-sarcopenic (N = 93) |
Ximen Community of Ningbo |
Sarcopenic 76.15 ± 0.58 years Non-sarcopenic 76.19 ± 0.58 years |
Hypertension, diabetes mellitus | Appendicular skeletal muscle mass (ASM); relative skeletal muscle mass index (ASM/Ht2) |
| Liu 2021 [82] | China | NR | 77 Sarcopenic (N = 18) Dynapenic (loss of muscular function without mass) (N = 35) Non-sarcopenic (N = 24) |
Community-dwelling older adults |
Female/male Sarcopenic 79.8 ± 5.9 years Dynapenic 80.2 ± 5.7 years Non-sarcopenic 75.8 ± 6.1 years |
None | Handgrip strength, gait speed |
| Valášková 2021 [83] | Slovakia | NR | 80 patients classified based on a short physical performance battery score (SPPB): Sarcopenia SPPB ≤ 6 (low muscle performance) (N = 31) Sarcopenia SPPB 7–9 (moderate muscle performance) (N = 17) Sarcopenia SPPB > 9 (high muscle performance) (N = 32) |
NR | Female/male 55–86 years |
NR | SPPB |